



AMIS Plus Newsletter Nr. 23 – September 2007

Dear Current & Potential AMIS Plus Participants & Sponsors

Slightly revised AMIS Plus Questionnaire

As announced, there have been a few changes made to the AMIS Plus Questionnaire. This slightly revised version – in operation since August 2007 – features:

- Extended information on bleeding as a complication during hospitalization
- Extended medication lists with regard to reported history and for immediate therapy
- Risk factors as reported history now also include possible alcohol and drug consumption

AMIS Plus at the ESC Congress 2007 from September 1-5, 2007 in Vienna, Austria

AMIS Plus was represented at the Annual Congress of the European Society of Cardiology (ESC) from September 1-5, 2007 in Vienna, Austria, with the following contributions:

- Better outcome with primary percutaneous coronary intervention in unselected patients with acute coronary syndrome. A report from the AMIS Plus registry. Erne P et al. (Oral Presentation).
- Determinants of costs and the length of stay in acute coronary syndromes: a real life analysis of more than 10 000 patients. Bramkamp M et al (Poster).
- Impact of comorbidities on survival of patients admitted for an acute coronary syndrome. Fassa A-A et al (Poster).

The **AMIS Plus** paper “**Determinants of costs and the length of stay in acute coronary syndromes: a real life analysis of more than 10 000 patients**” by Bramkamp M, Radovanovic D, Erne P Szucs has just been published online. DOI 10.1007/s10557-007-6044-0 available via <http://dx.doi.org/> [Published online: September 6, 2007]

We are introducing the new **AMIS Plus Highlights** box, which will now be included in every newsletter! This box provides you with an overview of the results and achievements of AMIS Plus.



AMIS Plus findings provide additional evidence highlighting the importance of statin therapy in the treatment of ACS. Chronic statin therapy seems to alter the initial presentation of ACS, but does not have an additional effect on early outcomes compared to statin therapy introduced after admission to statin-naive patients. High-risk populations, such as the elderly, diabetics or patients with renal failure benefit even more.


For more see new publication attached

DOI: 10.1159/000106676 available via <http://dx.doi.org/> [Published online: August 28, 2007]


We would like to thank all AMIS Plus participants and sponsors for their invaluable contribution! The AMIS Plus Project is made possible thanks to your continuous support. A warm welcome to the hospitals of **Aarau, Sursee, Einsiedeln** and **Bern Tiefenau**, who have recently joined AMIS Plus!

Sincerely yours

For the Steering Committee:


Prof. Paul Erne, MD
President

For the Data Center:


Dragana Radovanovic, MD
Head of the Data Center